What is the official ID of this bill?
The official print number for this legislation is HR 4813.
Matt's Act: Limiting Insulin Prices for Diabetics
This act aims to reduce insulin costs for individuals with diabetes, whether insured or uninsured. Insulin manufacturers will be required to publish average prices, and insurers and pharmacies must offer insulin at reduced rates, making the medication more accessible and easing financial burdens.
Key points
Insulin manufacturers must publish quarterly average net prices of their products online.
Insured individuals (group or individual plans) will pay no more than 10% of the average net price plus distribution costs, or $20, whichever is less. For high-deductible plans, insulin will be free.
Uninsured individuals can purchase insulin at pharmacies for the average net price plus distribution costs, which cannot exceed 10% of the average net price.
The act waives deductibles for insulin for insured individuals.
Distribution and dispensing charges for insulin cannot exceed 10% of the average net price of the drug.
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens
(explained here).
Start recording it now.